This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Exprivia Toekomstige groei

Future criteriumcontroles 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Exprivia.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

IT winstgroei	14.2%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Exprivia S.p.A.'s (BIT:XPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Apr 04

Does Exprivia (BIT:XPR) Have A Healthy Balance Sheet?

Mar 01

Exprivia (BIT:XPR) Is Looking To Continue Growing Its Returns On Capital

Feb 02

Does Exprivia (BIT:XPR) Have A Healthy Balance Sheet?

Nov 11

Exprivia (BIT:XPR) Takes On Some Risk With Its Use Of Debt

Jul 08

Should You Investigate Exprivia S.p.A. (BIT:XPR) At €1.32?

Jun 10

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Exprivia onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

BIT:XPR - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2023	197	13	14	17	N/A
9/30/2023	195	13	20	22	N/A
6/30/2023	186	12	14	16	N/A
3/31/2023	183	12	18	20	N/A
12/31/2022	178	12	12	14	N/A
9/30/2022	187	11	11	14	N/A
6/30/2022	184	11	13	15	N/A
3/31/2022	181	11	10	12	N/A
12/31/2021	179	10	16	19	N/A
9/30/2021	170	10	25	29	N/A
6/30/2021	168	9	34	38	N/A
3/31/2021	166	8	29	35	N/A
12/31/2020	164	9	31	36	N/A
9/30/2020	-99	164	35	31	N/A
6/30/2020	-5	78	37	36	N/A
3/31/2020	98	77	37	39	N/A
12/31/2019	165	70	28	33	N/A
9/30/2019	567	-82	30	46	N/A
6/30/2019	579	4	-2	14	N/A
3/31/2019	607	8	23	37	N/A
12/31/2018	615	0	15	31	N/A
9/30/2018	473	-5	-7	5	N/A
6/30/2018	367	-7	12	22	N/A
3/31/2018	235	-12	-4	4	N/A
12/31/2017	160	0	6	9	N/A
9/30/2017	153	-1	N/A	12	N/A
6/30/2017	148	2	N/A	10	N/A
3/31/2017	144	4	N/A	8	N/A
12/31/2016	140	3	N/A	12	N/A
9/30/2016	139	5	N/A	2	N/A
6/30/2016	137	4	N/A	3	N/A
3/31/2016	139	4	N/A	-3	N/A
12/31/2015	141	5	N/A	-1	N/A
9/30/2015	146	4	N/A	11	N/A
6/30/2015	148	4	N/A	11	N/A
3/31/2015	147	4	N/A	9	N/A
12/31/2014	144	4	N/A	14	N/A
9/30/2014	137	3	N/A	7	N/A
6/30/2014	135	3	N/A	10	N/A
3/31/2014	130	2	N/A	17	N/A
12/31/2013	128	2	N/A	12	N/A
9/30/2013	131	3	N/A	15	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Insufficient data to determine if XPR's forecast earnings growth is above the savings rate (2.3%).

Winst versus markt: Insufficient data to determine if XPR's earnings are forecast to grow faster than the Italian market

Hoge groeiwinsten: Insufficient data to determine if XPR's earnings are expected to grow significantly over the next 3 years.

Omzet versus markt: Insufficient data to determine if XPR's revenue is forecast to grow faster than the Italian market.

Hoge groei-inkomsten: Insufficient data to determine if XPR's revenue is forecast to grow faster than 20% per year.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Insufficient data to determine if XPR's Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Exprivia Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 20% to €1.60

Price target decreased to €2.00

Price target increased to €2.60

Recent updates

Investor sentiment deteriorates as stock falls 16%

Full year 2023 earnings released: EPS: €0.28 (vs €0.23 in FY 2022)

Exprivia S.p.A., Annual General Meeting, Apr 23, 2024

Insufficient new directors

Exprivia S.p.A. (BIT:XPR) Launches Binding Offer to acquire 85% stake in Balance Spa.

Price target decreased by 20% to €1.60

First half 2023 earnings released: EPS: €0.12 (vs €0.11 in 1H 2022)

Investor sentiment improves as stock rises 21%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings released: EPS: €0.055 (vs €0.053 in 3Q 2021)

Exprivia (BIT:XPR) Is Doing The Right Things To Multiply Its Share Price

Price target decreased to €2.00

Is It Time To Consider Buying Exprivia S.p.A. (BIT:XPR)?

Investor sentiment deteriorated over the past week

A Look At The Intrinsic Value Of Exprivia S.p.A. (BIT:XPR)

Exprivia (BIT:XPR) Shareholders Will Want The ROCE Trajectory To Continue

Second quarter 2022 earnings released: EPS: €0.056 (vs €0.059 in 2Q 2021)

Investor sentiment deteriorated over the past week

What Is Exprivia S.p.A.'s (BIT:XPR) Share Price Doing?

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of €0.048 per share

Price target increased to €2.60

Exprivia S.p.A.'s (BIT:XPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Does Exprivia (BIT:XPR) Have A Healthy Balance Sheet?

Exprivia (BIT:XPR) Is Looking To Continue Growing Its Returns On Capital

Third quarter 2021 earnings released: EPS €0.053 (vs €0.029 in 3Q 2020)

Does Exprivia (BIT:XPR) Have A Healthy Balance Sheet?

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS €0.059 (vs €0.042 in 2Q 2020)

Investor sentiment improved over the past week

Exprivia (BIT:XPR) Takes On Some Risk With Its Use Of Debt

Investor sentiment improved over the past week

Should You Investigate Exprivia S.p.A. (BIT:XPR) At €1.32?

New 90-day high: €0.86

New 90-day high: €0.84

New 90-day low: €0.62

New 90-day low: €0.66

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven